$0.86 Earnings Per Share Expected for Bristol-Myers Squibb Co (BMY) This Quarter

Equities research analysts forecast that Bristol-Myers Squibb Co (NYSE:BMY) will post $0.86 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Bristol-Myers Squibb’s earnings. The highest EPS estimate is $0.96 and the lowest is $0.74. Bristol-Myers Squibb reported earnings of $0.84 per share in the same quarter last year, which would indicate a positive year over year growth rate of 2.4%. The business is expected to report its next quarterly earnings results before the market opens on Thursday, April 26th.

According to Zacks, analysts expect that Bristol-Myers Squibb will report full-year earnings of $3.20 per share for the current year, with EPS estimates ranging from $3.10 to $3.28. For the next year, analysts expect that the company will post earnings of $3.77 per share, with EPS estimates ranging from $3.26 to $4.06. Zacks’ EPS averages are an average based on a survey of research firms that cover Bristol-Myers Squibb.

How to Become a New Pot Stock Millionaire

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.01. The company had revenue of $5.45 billion for the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The firm’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.63 EPS.

Several research firms recently weighed in on BMY. Leerink Swann upped their price target on Bristol-Myers Squibb from $71.00 to $76.00 and gave the stock a “positive” rating in a research note on Tuesday, February 6th. Vetr upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating and set a $60.72 price target on the stock in a research note on Thursday, February 1st. BMO Capital Markets cut their price target on Bristol-Myers Squibb from $52.00 to $51.00 and set an “underperform” rating on the stock in a research note on Tuesday, February 6th. Citigroup set a $78.00 price target on Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Friday, February 16th. Finally, Zacks Investment Research downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Monday, January 29th. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $66.30.

Bristol-Myers Squibb (BMY) traded up $0.35 during trading on Monday, hitting $66.60. The company had a trading volume of 7,989,357 shares, compared to its average volume of 5,784,397. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.43. The stock has a market cap of $108,158.63, a P/E ratio of 112.88, a P/E/G ratio of 2.03 and a beta of 0.98. Bristol-Myers Squibb has a 52 week low of $51.56 and a 52 week high of $70.05.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be paid a dividend of $0.40 per share. The ex-dividend date is Thursday, April 5th. This represents a $1.60 annualized dividend and a yield of 2.40%. Bristol-Myers Squibb’s dividend payout ratio is 271.19%.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its holdings in shares of Bristol-Myers Squibb by 16.0% during the 2nd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 388,247 shares of the biopharmaceutical company’s stock valued at $21,633,000 after buying an additional 53,468 shares during the period. BDO Wealth Advisors LLC bought a new position in shares of Bristol-Myers Squibb during the 2nd quarter valued at $123,000. Mitsubishi UFJ Trust & Banking Corp lifted its holdings in shares of Bristol-Myers Squibb by 1.4% during the 2nd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 3,434,153 shares of the biopharmaceutical company’s stock valued at $191,351,000 after buying an additional 46,301 shares during the period. Pacer Advisors Inc. lifted its holdings in shares of Bristol-Myers Squibb by 6.3% during the 2nd quarter. Pacer Advisors Inc. now owns 37,947 shares of the biopharmaceutical company’s stock valued at $2,114,000 after buying an additional 2,250 shares during the period. Finally, Tobam lifted its holdings in shares of Bristol-Myers Squibb by 38.1% during the 2nd quarter. Tobam now owns 1,096,089 shares of the biopharmaceutical company’s stock valued at $61,074,000 after buying an additional 302,375 shares during the period. Institutional investors and hedge funds own 71.55% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Markets Daily and is the property of of Markets Daily. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.themarketsdaily.com/2018/03/18/0-86-earnings-per-share-expected-for-bristol-myers-squibb-co-bmy-this-quarter.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Get a free copy of the Zacks research report on Bristol-Myers Squibb (BMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply